Search the Newsreel

The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS

The Manufacturers Life Insurance Company significantly increased its stake in Corvus Pharmaceuticals (NASDAQ:CRVS) by 481.7% in Q1, purchasing 84,282 shares to bring its total holdings to 101,779 shares valued at $1.49 million. Other institutional investors also expanded their positions, contributing to hedge funds and …

Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss?

Corvus Pharmaceuticals (CRVS) reported a wider Q2 2026 net loss, leading to a recent share price pullback despite strong longer-term momentum. Analysts have a consensus price target of $35, suggesting the stock is undervalued based on future earnings and growth assumptions, though its current …

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts

Corvus Pharmaceuticals (NASDAQ:CRVS) has received a "Moderate Buy" average recommendation from eight research firms, with an average 12-month price target of $33.33, significantly higher than its current share price of $13.92. Despite a recent quarterly loss that missed analyst expectations, institutional ownership is strong, …

Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS) reported a quarterly loss of $0.19 per share, missing analyst expectations by $0.03. Despite the earnings miss, the company extended its cash runway into Q2 2028 after a $189.4 million follow-on offering and reported encouraging Phase I results for soquelitinib in …

Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar

Corvus Pharmaceuticals reported a Q2 2026 net loss of $18 million, more than double the previous year, primarily due to increased R&D spending on its lead drug candidate, soquelitinib. Despite the wider loss, the company has a strong cash position of $215.2 million, projected …

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

Corvus Pharmaceuticals reported its second-quarter 2026 financial results, highlighting that its cash, cash equivalents, and marketable securities reached $215.2 million, providing a runway into Q2 2028. The company is actively enrolling patients in Phase 3 trials for soquelitinib in relapsed/refractory peripheral T-cell lymphoma (PTCL) …

Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Corvus Pharmaceuticals 2Q 2026: Net income $(17.96)M, EPS $(0.19) — 10-Q Summary

Corvus Pharmaceuticals reported a wider net loss of $(17.96)M and diluted EPS of $(0.19) for Q2 2026, compared to the year-ago quarter, as the company continues to invest heavily in clinical development. Despite the increased losses and no product revenue, Corvus Pharmaceuticals is progressing …

Corvus Eczema Trial Is Expected to Enroll About 200 Patients

Corvus Pharmaceuticals reported a Q2 2026 net loss of $18.0 million, an increase from $8.0 million a year prior, primarily due to higher clinical trial and personnel costs for soquelitinib. The company maintains a strong cash position of $215.2 million, expected to fund operations …

Corvus Pharmaceuticals earnings up next as trial progress eyed

Corvus Pharmaceuticals is set to release its second-quarter earnings, with investors focused on clinical trial progress for its lead drug candidate, soquelitinib, and its cash burn rate. The pre-revenue biotech is expected to post a loss of 15 cents per share, with current cash …

Corvus Pharmaceuticals Q2 Earnings Call Highlights

Corvus Pharmaceuticals reported a wider Q2 loss due to increased R&D spending on soquelitinib trials, but its substantial cash position is expected to fund operations into Q2 2028. The company provided updates on its clinical programs, including the Phase III PTCL trial with an …

Corvus Pharmaceuticals schedules Q2 financial results conference call and webcast

Corvus Pharmaceuticals announced it will hold a conference call and webcast on August 6, 2026, to provide a business update and discuss its second-quarter 2026 financial results. The information was initially published by Corvus Pharmaceuticals Inc. on July 30, 2026, and this news brief …

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

Corvus Pharmaceuticals will host a conference call and webcast on August 6, 2026, at 4:30 pm ET to provide a business update and report its second-quarter 2026 financial results. The clinical-stage biopharmaceutical company is focused on developing ITK inhibition for immune diseases and cancer, …

Corvus Pharmaceuticals' Q2 Business Update Will Stream Live Aug. 6

Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on August 6, 2026, at 4:30 pm ET to provide a business update and report its second-quarter 2026 financial results. Investors can join by dialing in or accessing the live webcast via the …

Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Corvus Pharmaceuticals Inc (CRVS), indicating that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. Despite this, it displays current stock data for CRVS, including its market cap …

BlackRock (CRVS holder) reports 7.5% beneficial stake in Corvus Pharmaceuticals

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a passive ownership stake of 7.5% in Corvus Pharmaceuticals, Inc. common stock. This represents 6,325,157 shares, with BlackRock holding sole voting power over 6,217,422 shares and sole dispositive power over all 6,325,157 shares. No single …

Corvus Pharmaceuticals Inc (CRVS) Financial Health: Profitability & Balance Sheet Analysis

This article provides an overview of Corvus Pharmaceuticals Inc's (CRVS) financial health, focusing on profitability and balance sheet analysis. It includes current stock price data, market capitalization, and links to more detailed financial discussions and analysis on the TradingKey platform. The content is an …

CRVS|Corvus Pharmaceuticals Inc|Price:13.610|Chg%:+0.540

This article provides an analysis of Corvus Pharmaceuticals Inc (CRVS) using TradingKey's stock score system. It outlines the methodology behind generating various scores such as financial health, company valuation, earnings forecast, price momentum, institutional confidence, and risk management. The article notes that no stock …

Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Corvus Pharmaceuticals Inc (CRVS), including its stock price, market cap, and a note that P/E, P/B, and P/CF data are not yet disclosed by the company. It lists various sections for stock analysis like Financials, Discussions, Analysis, …

Corvus Pharmaceuticals Inc (CRVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Corvus Pharmaceuticals Inc (CRVS), detailing its support, resistance, and various indicator readings. It covers commonly used technical indicators like MACD, RSI, and moving averages, offering a summary of buy, sell, and neutral signals. The analysis aims to …

Corvus Pharmaceuticals director Ian T. Clark resigns from board

Corvus Pharmaceuticals director Ian T. Clark has resigned from the company's board of directors, effective July 22, 2026. Clark provided notice of his intention to resign the day prior, on July 21, 2026. This news brief was generated by Public Technologies (PUBT) using AI, …

Corvus Pharmaceuticals (CRVS) Q1 2026 earnings summary

Corvus Pharmaceuticals (CRVS) reported a net loss of $13.7 million for Q1 2026, a significant decrease from a net income of $15.2 million in Q1 2025 which was largely due to a non-cash gain. The company's operations are focused on advancing its lead candidate, …